ECI Biotech Doubles Space in New Worcester Location

ECI Biotech, a Worcester company specializing in research and development of new protein technologies, has moved its headquarters to 6 Park Avenue in Worcester.

For Immediate Release
Contact: Steve Dubin, PR Works, (781) 878-9533, sdubin@prworkzone.com

ON THE MOVE
ECI Biotech Doubles Space in New Worcester Location

DATELINE: WORCESTER, MA; ISSUED JUNE 7, 2002 . . .
ECI Biotech, a Worcester company specializing in research and development of new protein technologies, has moved its headquarters to 6 Park Avenue in Worcester.

ECI's new research and development labs now occupy 5700 square feet -- nearly double the size of their previous space. ECI has constructed a state-of-the-art protein engineering, assay development, and tissue culture facility for its research in rapid point-of-care pathogen and toxin sensor technologies.

"We are very excited about our new location," said Dr. Mitchell Sanders, founder and President of ECI Biotech. "The proximity to Worcester Polytechnic Institute is a major advantage for us. As an affiliate professor at WPI, we have access to some most talented students in the region . We hire the students very early in their academic careers from work study to their major qualifying projects (MQP) and then we hire them when they graduate. Our company was founded on strong science and the ability to attract a dedicated team of workers and the majority of our employees have been graduates of WPI."

ECI recently formed a partnership with Chelmsford, Massachusetts-based ESA, Inc., the world leader in blood lead detection, to develop innovative products for the detection and removal of lead.

ECI Biotech is a Worcester, Massachusetts company engaged in breakthrough research on protein design and expression. The company is committed to developing and licensing its protein technologies for use in large industries with unmet needs, including food safety, medical diagnostics, industrial chemistry and consumer goods. ECI Biotech's product pipeline currently includes a diagnostic kit for detecting the pathogenic bacteria Listeria monocytogenes, as well as advanced wound care systems designed to provide early warning of emergent infections and to promote healing.

For more information about ECI Biotech and its protein technologies, please visit www.ecibiotech.com, or contact Dr. Mitchell Sanders at (508) 752-2209.

###